Law firms representing women harmed by surgical mesh used in breast reconstruction, augmentation, and internal bra procedures can partner with Atraxia Media to acquire qualified clients.
Families injured by defective breast mesh products deserve strong legal representation. Our team has the marketing experience to connect these cases with the right personal injury firms.
Atraxia Media helps you grow your case inventory and supports you with onboarding, intake review, client communication, and marketing strategy, getting you breast mesh cases that meet your criteria and significantly boosting your firm's visibility.
Current signed contract costs: ***subject to change
The reliable and experienced team of marketing professionals at Atraxia Media uses the most effective approach to find and onboard clients who are a good fit for your law firm based on your criteria. The marketing strategy that helps us find women affected by defective breast mesh products can be divided into the following stages:
Women may be eligible to file a claim for breast mesh injuries if they:
From our first interaction with a potential client until the moment they sign the engagement letter, we handle everything, including ad development, social media buying, and screening. We only need to know the number of breast mesh cases your law firm would like to receive. Atraxia Media's marketing process is more than just securing potential clients. It is a whole process of attracting and signing new clients as per your needs.
Beginning in the early 2000s, manufacturers introduced synthetic and biologic mesh products through the FDA's 510(k) clearance pathway for soft-tissue reinforcement and general surgical repair. These products were not cleared specifically for breast surgery. Despite the absence of breast-specific FDA clearance, surgeons began using these products in breast reconstruction, augmentation, revision surgeries, and internal bra procedures throughout the 2010s as the technique gained popularity among plastic surgeons.
The internal bra procedure involves implanting a mesh scaffold inside the breast to support implants, reinforce weakened tissue, improve implant positioning, and reduce sagging. Manufacturers marketed their products for soft-tissue support while surgeons applied them in breast procedures that fell outside the scope of any existing FDA clearance. Plaintiffs in active investigations allege that manufacturers knew their products were being widely used in breast surgery without sufficient testing for that specific purpose and failed to disclose the risks that breast-specific use carried.
Between 2015 and 2020, complication reports were accumulating in step with the wider use of mesh in breast procedures. Patients were coming forward with infections, seromas, implant loss, capsular contracture, chronic pain, wound breakdown, and revision surgeries at rates that drew serious scrutiny from researchers and regulators. The FDA put out a safety communication in March 2021 covering acellular dermal matrix products used in breast reconstruction, flagging data that showed certain products, including FlexHD and AlloMax had significantly higher rates of infection, reoperation, and implant removal than comparable alternatives.
The most important regulatory development in this litigation was the FDA Letter to Health Care Providers in November 2023, which mandated that Becton Dickinson include new warnings for its mesh products: GalaFLEX, GalaFLEX Lite, Phasix, and Phasix ST. The FDA said outright that the safety and effectiveness of surgical mesh in breast surgery had not been established, and that no mesh product had been cleared or approved for breast augmentation, reconstruction, mastopexy, or internal bra procedures. That letter set national legal investigations in motion and triggered a wave of case screening activity across plaintiff firms.
BREAST MESH LITIGATION
Location: Individual state and federal courts nationwide; no federal MDL currently exists
Presiding Authority: Various state and federal judges across individual product liability proceedings; no centralized presiding judge as consolidation has not yet occurred
Plaintiffs: Women who underwent breast reconstruction, augmentation, internal bra procedures, or implant revision surgeries involving surgical mesh and subsequently experienced infections, implant loss, capsular contracture, chronic pain, mesh failure, cosmetic deformity, or underwent revision surgeries, and who were not informed that no surgical mesh product carried FDA clearance specifically for breast surgery
Defendants:
Products: Synthetic and biologic surgical mesh products implanted during breast reconstruction, augmentation, internal bra procedures, and implant revision surgeries, including GalaFLEX, Phasix, AlloDerm, FlexHD, AlloMax, and Strattice, none of which carry FDA clearance or approval specifically for breast surgery
Plaintiff Allegations: Those filing suit claim manufacturers promoted and sold surgical mesh products for use in breast procedures despite the FDA never clearing or approving any surgical mesh specifically for breast augmentation, reconstruction, breast lifts, or internal bra procedures. Plaintiffs allege manufacturers knew their products were being widely used in breast surgery and failed to conduct breast-specific safety testing or provide adequate warnings to surgeons and patients about the risks that breast-specific use carried. The 2021 FDA safety communication on ADM products and the November 2023 labeling action are regularly cited in support of allegations that manufacturers had access to complication data and failed to warn the medical community in time. The claims involve failure to warn, off-label promotion, defective design, and a lack of adequate testing specifically for breast procedures.
History:
2024 to 2026:
The FDA's labeling action of November 2023 opened the floodgates for legal investigations on a national scale. Plaintiff firms began advertising for breast mesh claims, taking screening cases for GalaFLEX, Phasix, AlloDerm, FlexHD, etc. Throughout 2025 and 2026, individual lawsuits popped up in various jurisdictions as women reported infections, chronic pain, capsular contracture, implant loss, and repeat surgeries. As of 2026, no bellwether trials have taken place, no settlement program exists, and no federal MDL has been created. Many mass tort observers see the current state of breast mesh litigation as similar to where hernia mesh and transvaginal mesh cases were before those proceedings were consolidated.
November 2023:
The FDA issued a Letter to Health Care Providers requiring updated warning labels for Becton Dickinson mesh products including GalaFLEX, GalaFLEX Lite, Phasix, and Phasix ST, stating explicitly that the safety and effectiveness of surgical mesh in breast surgery had not been determined. The agency reiterated that no surgical mesh product had been cleared or approved for breast augmentation, reconstruction, mastopexy, or internal bra procedures. This action marked the most significant regulatory development in the litigation and directly accelerated national case screening activity.
2021 to 2022:
The FDA issued a safety communication in March 2021 regarding acellular dermal matrix products used in implant-based breast reconstruction, identifying data showing that products including FlexHD and AlloMax had significantly higher rates of infection, reoperation, and implant removal compared to some alternatives. The agency did not issue a recall, but the communication drew regulatory attention to complication patterns that plaintiffs argue should have prompted stronger warnings and additional studies years earlier.
Early 2000s to 2020:
Manufacturers introduced synthetic and biologic mesh products through the FDA's 510(k) clearance pathway for soft-tissue reinforcement without breast-specific clinical testing. Surgeons began adopting the internal bra technique between 2010 and 2015, applying mesh products in breast procedures despite the absence of FDA clearance for those indications. Complication reports involving infection, seroma, implant loss, capsular contracture, and revision surgery accumulated between 2015 and 2020 as the use of mesh in breast procedures expanded nationally.
Atraxia Media has spent 25 years watching mass torts move from early investigation to consolidation, and breast mesh carries the regulatory foundation and injury profile that tend to precede major litigation. The FDA's November 2023 labeling action handed plaintiff firms the evidentiary footing they needed to act, and individual filings are accelerating across multiple jurisdictions. Firms that build inventory before an MDL forms will hold the strongest negotiating position when global resolution discussions begin. Contact Atraxia Media today to discuss how we can help your firm get ahead of the consolidation curve on breast mesh.